Dominika Labuz

Dominika Labuz

Auto-generated profile, based on publicly available information

Dominika Labuz

Department of Experimental Anesthesiology, Charité-Universitätsmedizin Berlin, Berlin 12203, Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2017 in Science
Verified
Journal Article
Closed access
PDF file
VSV. Spahn
V. Spahn
GVG. Del Vecchio
G. Del Vecchio
DLD. Labuz
D. Labuz
ARA. Rodriguez-Gaztelumendi
A. Rodriguez-Gaztelumendi
NMNicolas Massaly
Nicolas Massaly
CSChristoph Stein
Christoph Stein
A pain killer without side effects: Opioids are very strong and effective pain killers. However, they also have a range of well-known side effects and can cause addiction. Painful conditions such as inflammation or trauma are often associated with localized tissue acidification. Spahn et al. designed a novel opioid receptor agonist that, unlike clinically used opioids, best activates the receptors in such acidified tissues. In rat models of inflammatory pain, the new drug exerted strong pain relief essentially without the side effects of standard opioids. Science , this issue p. 966

16 February 2021 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
DLDominika Labuz
Dominika Labuz
MCMelih Özgür Celik
Melih Özgür Celik
VSViola Seitz
Viola Seitz
HMHalina Machelska
Halina Machelska
Interleukin-4 (IL-4) is an anti-inflammatory cytokine, which can be protective in inflammatory and neurologic disorders, and can alleviate pain. Classically, IL-4 diminishes pain by blocking the production of proinflammatory cytokines. Here, we uncovered that IL-4 induces acute antinociception by IL-4 receptor α (IL-4Rα)-dependent release of opioid peptides from M1 macrophages at injured nerves. As a model of pathologic pain, we used a chronic constriction injury (CCI) of the sciatic nerve in male mice. A single application of IL-4 at the injured nerves (14 d following CCI) attenuated mechanical hypersensitivity evaluated by von Frey filaments, which was reversed by co-injected antibody to IL-4Rα, antibodies to opioid peptides such as Met-enkephalin (ENK), β-endorphin and dynorphin A 1–17, and selective antagonists of δ-opioid, µ-opioid, and κ-opioid receptors. Injured nerves were predominately infiltrated by proinflammatory M1 macrophages and IL-4 did not change their numbers or the phenotype, assessed by flow cytometry and qRT-PCR, respectively. Macrophages isolated from damaged nerves by immunomagnetic separation (IMS) and stimulated with IL-4 dose dependently secreted all three opioid peptides measured by immunoassays. The IL-4-induced release of ENK was diminished by IL-4Rα antibody, intracellular Ca2+chelator, and inhibitors of protein kinase A (PKA), phosphoinositide 3-kinase (PI3K), and ryanodine receptors. Together, we identified a new opioid mechanism underlying the IL-4-induced antinociception that involves PKA-mediated, PI3K-mediated, ryanodine receptor-mediated, and intracellular Ca2+-mediated release from M1 macrophages of opioid peptides, which activate peripheral opioid receptors in injured tissue.SIGNIFICANCE STATEMENTInterleukin-4 (IL-4) is an anti-inflammatory cytokine, which can ameliorate pain. The IL-4-mediated effects are considered to mostly result from the inhibition of the production of proinflammatory mediators (e.g., IL-1β, tumor necrosis factor, prostaglandin E2). Here, we found that IL-4 injected at the injured nerves attenuates pain by releasing opioid peptides from the infiltrating macrophages in mice. The opioids were secreted by IL-4 in the intracellular Ca2+-dependent manner and activated local peripheral opioid receptors. These actions represent a novel mode of IL-4 action, since its releasing properties have not been so far reported. Importantly, our findings suggest that the IL-4–opioid system should be targeted in the peripheral damaged tissue, since this can be devoid of central and systemic side effects.

4 July 2017 in eLife
Verified
Journal Article
Open access
SGSara González-Rodríguez
Sara González-Rodríguez
MQMohiuddin A Quadir
Mohiuddin A Quadir
SGShilpi Gupta
Shilpi Gupta
KWKarolina A Walker
Karolina A Walker
XZXuejiao Zhang
Xuejiao Zhang
CSChristoph Stein
Christoph Stein
Novel painkillers are urgently needed. The activation of opioid receptors in peripheral inflamed tissue can reduce pain without central adverse effects such as sedation, apnoea, or addiction. Here, we use an unprecedented strategy and report the synthesis and analgesic efficacy of the standard opioid morphine covalently attached to hyperbranched polyglycerol (PG-M) by a cleavable linker. With its high-molecular weight and hydrophilicity, this conjugate is designed to selectively release morphine in injured tissue and to prevent blood-brain barrier permeation. In contrast to conventional morphine, intravenous PG-M exclusively activated peripheral opioid receptors to produce analgesia in inflamed rat paws without major side effects such as sedation or constipation. Concentrations of morphine in the brain, blood, paw tissue, and in vitro confirmed the selective release of morphine in the inflamed milieu. Thus, PG-M may serve as prototype of a peripherally restricted opioid formulation designed to forego central and intestinal side effects.